What are brand histories?

Brand histories are structured narratives that document how companies were founded, scaled, pivoted, and competed over time using verified business data.

Where can I read company histories?

You can read company histories on BrandHistories.com, including profiles across industries, timelines, and strategic analysis.

Why study business histories?

Studying business histories helps founders, investors, and researchers understand strategic decisions, failure patterns, and long-term competitive advantages.

What does Johnson & Johnson do?

Johnson & Johnson is an American multinational healthcare corporation involved in pharmaceuticals, medical devices, and consumer health products. Founded in 1886 in New Brunswick, New Jersey by brothers Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, the company initially focused on manufacturing sterile surgical dressings. At the time, advances in antiseptic surgical practices were increasing demand for sterile medical supplies, and the founders recognized an opportunity to produce standardized medical products for hospitals and physicians. The company expanded rapidly in the late nineteenth and early twentieth centuries by introducing new healthcare products designed for professional medical use as well as household health needs. One of Johnson & Johnson's early innovations was the mass production of sterile surgical supplies, which helped improve hygiene standards in medical procedures. The company later introduced widely used consumer healthcare products such as baby powder, adhesive bandages, and over-the-counter medicines. Throughout the twentieth century Johnson & Johnson diversified its operations through acquisitions and internal research programs. The company developed a decentralized management structure that allowed individual subsidiaries to operate independently while benefiting from shared corporate resources. This approach enabled Johnson & Johnson to expand across multiple healthcare segments including pharmaceuticals, biotechnology, and medical technology. Today Johnson & Johnson operates globally through multiple business divisions focused on pharmaceuticals and medical technologies. Its product portfolio includes treatments for cancer, immunology disorders, cardiovascular diseases, and infectious diseases. The company also develops surgical equipment and medical devices used in hospitals worldwide. Johnson & Johnson remains one of the largest healthcare companies in the world and continues investing in scientific research, biotechnology, and medical innovation to address global health challenges.

Who is the CEO of Johnson & Johnson?

The current CEO of Johnson & Johnson is Joaquin Duato.

When was Johnson & Johnson founded?

Johnson & Johnson was founded in 1886 by Robert Wood Johnson, James Wood Johnson, Edward Mead Johnson, based in New Brunswick, New Jersey.

What is Johnson & Johnson's market cap?

As of 2026, Johnson & Johnson's market capitalization is approximately $380 billion, making it one of the significant players in the Technology industry.

How Much Does Johnson & Johnson Make? Revenue Breakdown & Growth Data (2026)

Financial Narrative

Johnson & Johnson's financial profile following the Kenvue separation is that of a focused, high-margin pharmaceutical and medical device company with exceptional cash generation, a strong balance sheet, and a capital allocation strategy oriented toward R&D investment, bolt-on acquisitions, and consistent shareholder returns. Total revenue for 2023 (from continuing operations, excluding Kenvue) was approximately $85.2 billion, with Innovative Medicine contributing approximately $55 billion and MedTech approximately $30 billion. This revenue base reflects one of the broadest and most durable revenue portfolios in healthcare — no single product represents more than approximately 12% of total revenue, and geographic diversification across the US (approximately 55%), international markets (approximately 45%) provides additional resilience. Operating margins in the Innovative Medicine segment, reflecting J&J's premium positioning and pricing power for genuinely innovative biologics and specialty pharmaceuticals, are among the highest in the pharmaceutical industry. Adjusted operating margins of 35-40% on pharmaceutical revenue translate to substantial free cash flow generation that funds R&D investment while providing significant shareholder returns. MedTech margins (approximately 20-25% adjusted operating margin) are lower but still above the medical device industry average, reflecting J&J's premium product positioning and the recurring nature of implant revision revenue. Free cash flow generation has consistently exceeded $15 billion annually, providing extraordinary capital deployment flexibility. J&J has maintained a AAA credit rating — one of only two US companies to hold this rating alongside Microsoft — a distinction that reflects both financial strength and the consistency of cash generation through economic and therapeutic cycles. This financial stability enables J&J to make long-duration R&D and capital investments that shorter-horizon competitors cannot sustain. The pipeline of acquisitions has been a significant capital deployment channel. J&J's acquisition of Shockwave Medical (2024) for approximately $13.1 billion, Abiomed (2022) for approximately $16.6 billion, and multiple smaller acquisitions in oncology, immunology, and MedTech reflect a consistent strategy of acquiring clinical-stage or commercial-stage assets that accelerate the therapeutic portfolio beyond what internal discovery alone would produce. These acquisitions are funded from operating cash flow and debt issuance at J&J's AAA-rated borrowing cost — providing a capital cost advantage in acquisition competition against smaller pharmaceutical companies. The biosimilar erosion of Stelara beginning in 2023-2024 — with multiple biosimilar approvals reducing revenue from approximately $10 billion annual peak — represents the most significant near-term revenue headwind. Management has been transparent about this expected erosion and has positioned the Innovative Medicine segment's growth story around the offsetting trajectory of Darzalex, Tremfya, Carvykti, and new pipeline launches.

Johnson & Johnson Revenue Breakdown & Fiscal Growth

Key Takeaways

Financial Narrative

Frequently Asked Questions

Deep Dive: Johnson & Johnson Analysis